New EU approval for GSK’s Zejula
Zejula is the first PARP inhibitor to be approved as monotherapy in the EU for patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status
Read More
Tag: maintenance
NICE turns down Celgene’s Revlimid as multiple myeloma maintenance treatment
The drug’s cost-effectiveness estimate when used in the maintenance setting is uncertain, the Institute has concluded
Read More
Priority review for AZ/MSD’s Lynparza in first-line maintenance setting
US regulators have accepted an application from AstraZeneca and MSD for use of Lynparza as maintenance treatment for patients with newly-diagnosed, BRCA-mutated advanced ovarian cancer.
Read More
Clovis’ PARP inhibitor Rubraca under EU review in maintenance setting
European regulators have agreed to review Clovis’ application to expand the use of its PARP inhibitor Rubraca in the region.
Read More
Phase III success for Janssen’s esketamine in treatment-resistant depression
Janssen has presented data from pivotal Phase III clinical studies backing use of esketamine spray in treatment-resistant depression.
Read More
AZ/MSD’s Lynparza wins new CHMP nod
AstraZeneca and MSD’s Lynparza is a step closer to being cleared in Europe as maintenance therapy for some patients with ovarian cancer.
Read More
Revlimid boosts survival in myeloma patients post-transplant
Celgene has unveiled a meta-analysis of pooled data from three late-stage studies showing a significant overall survival benefit in patients newly diagnosed with multiple myeloma receiving Revlimid as maintenance therapy following autologous stem cell transplantation.
Read More
AZ’ Lynparza hits targets in ovarian cancer trial
AstraZeneca has unveiled data from a late-stage trial showing that Lynparza improved progression free survival (PFS) in patients with a certain form of ovarian cancer when used in the maintenance setting.
Read More
AZ’ Lynparza delays ovarian cancer progression, data show
A twice-daily dose of AstraZeneca’s Lynparza held off progression of ovarian cancer in certain patients when used as a maintenance treatment during a late-stage trial.
Read More
Lilly’s Alimta wins NICE support
NHS use of Eli Lilly’s Alimta to treat patients with lung cancer has been endorsed in final draft guidance from the National Institute for Health and Care Excellence.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
